SecBot SecBot
PRESS-RELEASE ·Filed May 29, 2026

MNKD

MannKind
BULLISH
Impact 8/10
Horizonimmediate Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a material catalyst for MNKD, Afrezza's only marketed product now has a major label expansion into a large, needle-averse pediatric population. Traders should watch for prescription volume data over the next 2-4 quarters as a read on commercial uptake. The stock may gap up significantly on this news given the $1.1B market cap and largely adult-only revenue base prior to approval.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.77
T+0 close · May 29, 2026 · via day close
Latest settled
+7.96%
T+60 · $4.07
Vs SPY
+6.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 29 $3.77entry
  2. T+1 · 6mo ago −6.37%α −6.64% · $3.53
  3. T+5 · 6mo ago −10.88%α −10.58% · $3.36
  4. T+20 · 5mo ago +12.47%α +14.26% · $4.24
  5. T+60 · 3mo ago +7.96%α +6.77% · $4.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind announced FDA approval of Afrezza (inhaled insulin) for pediatric patients aged 6+ with type 1 and type 2 diabetes. This expands Afrezza's addressable population by >350,000 US children/adolescents with diabetes and represents a significant label expansion for MannKind's only marketed product. The approval is based on the Phase 3 INHALE-1 trial and 20+ years of safety data.

Key Facts

  • FDA approved Afrezza for children/adolescents aged 6+ with type 1 and type 2 diabetes
  • Over 350,000 US children/adolescents have diabetes, mostly type 1 requiring lifelong insulin
  • Approval supported by Phase 3 INHALE-1 trial and 20+ years of clinical data
  • Eligible patients pay $35/month or less through MannKind Cares
  • Afrezza is the only ultra rapid-acting inhaled insulin and was previously approved only for adults (2014)

Financial Impact

Expands TAM by ~350K pediatric diabetes patients in the US; current MNKD market cap ~$1.1B. The pediatric approval likely adds $100-300M+ in peak revenue opportunity (based on typical inhaled insulin penetration) but exact figures are not stated.

revenuemarket shareprescription volume

Risk Factors

  • Afrezza's commercial adoption in adults has been slow since 2014 launch; pediatric uptake may face similar barriers
  • Competing with entrenched injectable insulin analogs and pumps; insurance coverage/reimbursement challenges
  • Potential lung function concerns in growing children, long-term safety data are limited
  • Black-box warning for bronchospasm in patients with chronic lung disease limits target population

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303734

Track record

17 reports on MNKD

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026